Insider Brief:
- Quantum Computing Inc. is partnering with Sanders Tri-Institutional Therapeutics Discovery Institute to advance computational biomedicine using QCi’s Dirac-3 Entropy Quantum Computing Machine.
- Sanders TDI, a collaboration of Kettering Cancer Center, The Rockefeller University, and Memorial Sloan Weill Cornell Medicine, focuses on preclinical biological research, disease prevention, and technical support for academic research.
- QCi’s Dirac-3 system, operating at room temperature and low power, will enable Sanders TDI to perform biomolecular modeling simulations for drug design and disease mechanism studies.
PRESS RELEASE — In a recent release, Quantum Computing Inc., a company specializing in integrated photonics and quantum optics, announced a collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI), a non-profit drug discovery organization. This partnership is intended to support research in computational biomedicine by providing access to QCi’s Dirac-3 Entropy Quantum Computing Machine.
UNITED INSTITUTIONS FOR BIOMEDICAL RESEARCH
Sanders TDI, based in New York City, is a collaboration between three renowned institutions: Kettering Cancer Center, The Rockefeller University, and Memorial Sloan Weill Cornell Medicine. The organization focuses on advancing biological research to preclinical studies, with a specific emphasis on disease prevention and treatment. Sanders TDI also provides technical support for academic research initiatives at a scale typically found in industrial settings.
THE DIRAC-3 QUANTUM COMPUTING MACHINE
Through this collaboration, QCi will grant Sanders TDI cloud-based access to the Dirac-3 system. As reported in the release, this quantum machine operates at room temperature, uses minimal power, and is specifically designed for optimization problems—mathematical challenges where the best solution must be identified from a large set of possibilities.
The Dirac-3 system will be used for proof-of-concept calculations in biomolecular modeling, an important component in computational chemistry. Biomolecular modeling uses simulations to predict the behavior of biological molecules which is highly relevant for both drug design and understanding disease mechanisms.
According to Dr. William McGann, QCi’s CEO, “We are truly excited to be a part of this strategic collaboration with Sanders TDI and to have our Dirac-3 systems support their efforts in rapidly assessing the efficacy of targeted therapeutics in treating human diseases. This partnership exemplifies how QCi’s quantum machines can provide powerful insights and useful analyses today. It aligns perfectly with our mission to make quantum machines accessible and affordable and is one of the many real-world applications where the power of quantum computing is being demonstrated and put into practice by QCi.”
QCi’s quantum technology, which includes quantum analog computers, is expected to support Sanders TDI’s research by performing calculations that could provide insights beyond the capabilities of classical computing methods. Both organizations will work together to identify and explore applications that demonstrate the most potential for QCi’s technology in advancing therapeutic research.
